Virtual Library
Start Your Search
M. Kamel
Author of
-
+
P1.06 - Poster Session with Presenters Present (ID 458)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.06-033 - Non-Small Cell Lung Cancer in Young Patients; Clinico-Pathologic Criteria and Prognostic Factors (ID 3809)
14:30 - 15:45 | Author(s): M. Kamel
- Abstract
Background:
A cancer registry was analyzed to determine the clinicopathologic characteristics and prognosis of non-small cell lung cancer (NSCLC) in patients < 45 years old at diagnosis as they were not thoroughly investigated
Methods:
Among enrolled NSCLC cases attending National Cancer Institute –Cairo (NCI) between 2007-2012, we retrospectively reviewed those who were 45 years old or younger. Data regarding demographics, ECCOG-performance status(PS), histology, grade, stage, chemotherapy type, number of cycles, overall and progression free survival (OS, PFS) were obtained. Pearson’s (X[2]) test , Cox regression and Kaplan-Meier survival curves were used for statistical analysis.
Results:
Among 99 NSCLC cases, we identified 22cases ≤ 45years. Lower stages were more prevalent among young (77.3%) versus old group(54.5%) p=0.05 Median OS in young versus old group was 18 versus 15 months(p=0.773), while PFS was 4 versus 6 months respectively (p=0.322) In our subgroup analysis(n=22); median age was 42years(30-45years), Nearly three-quarters were males, 40.9% were PS >1. The majority of cases in young group were stage IIIB(77.3.%). Pathology was squamous(40.9%), adenocarcinoma(22.7%), undifferentiated(22.7%) and adenosquamous carcinoma in 4.5% of our cases. Median OS and PFS was 18 and 4 months respectively. Significant difference in OS and PFS was observed among responder versus non responders in multivariate analysis (Figure)
Conclusion:
Good response to chemotherapy is the best way to prolong survival among young NSCLC cases irrespective of PS, gender, stage or pathology. Figure 1
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-001 - Advanced Large Cell Lung Cancer; Biological Behavior and Prognostic Factors (ID 3810)
14:30 - 15:45 | Author(s): M. Kamel
- Abstract
Background:
Large cell lung cancer (LCLC) is a newly recognized clinicopathologic entity. The clinical criteria and optimal treatment for patients with LCLC are not yet established. The aim of this study is to understand the clinicopathologic criteria of LCLC.
Methods:
Among enrolled NSCLC cases attending National Cancer Institute –Cairo (NCI) between 2012-2014, we retrospectively reviewed those had LCLC. Data regarding demographics, ECCOG-performance status(PS), tumor histology, grade and stage, chemotherapy type, number of cycles, response to chemotherapy, overall and progression free survival(OS, PFS) were retrieved. Pearson’s(X[2])test and Kaplan-Meier survival curves were used in statistical analysis.
Results:
Among 99 NSCLC cases, we identified squamous cell carcinoma (35.4%), adenocarcinoma(29.3%), ,undifferentiated(20.2%),large cell carcinoma (12.1%) and adenosquamous carcinoma(3%). Among 12 LCLC cases; median age was 52years (range;41-62years), Male : Female was 3:1. Three-quarters of our cohort were PS=1. Progressive disese occurred in 58.3%. All were grade 3. Near 60% were stage IV while stage IIIB represents the remaining. Median OS was not reached while mean OS was 16.2 months. Median PFS was 6 months. Nearly 90% of disease progression were found within 1 year after start of chemotherapy. There was no difference in median OS or PFS in LCLC vs other NSCLC(OS= not reached vs 13 months in other NSCLC(p=0.372) while PFS=6months in both groups(p= 0.915)). Further analysis by stage was conducted and revealed same results(in STAGE III; median OS not reached,mean OS was 18.2 vs 19.1for other NSCLC(p=0.400),median PFS was 8 vs 6monthsin other NSCLC(p=0.948). In STAGE IV; median OS was 12 vs 9 months (p=0.511), median PFS was 5months in both groups (p=0.956) See figure.
Conclusion:
Most cases of LCLC represents high grade tumors and indeed aggressive treatment is warranted. Although previously reported data revealed poor prognosis of LCLC (stage-I) in comparison to other NSCLC, our cohort represents similar prognosis in both groups in advanced stagesFigure 1
